During the corresponding time, Ptc Therapeutics Inc saw a revenue deteriorated by -76.83 % year on year, sequentially revenue grew by 65.51 %. While revenue at the Ptc Therapeutics Inc 's corporate clients
Ptc Therapeutics Inc's Comment on Sales, Marketing and Customers
In 2025, the company's product revenue was primarily derived from sales of Translarna for nmDMD, Emflaza for DMD, and Sephience for PKU. Sephience and Emflaza are commercially available throughout the United States and distributed through five specialty pharmacies that ship directly to patients based on physician prescriptions. Payors for these products in the U.S. are typically state health insurance programs or third-party health insurers. Sephience is also commercially available in the European Economic Area (EEA) and other regions. Translarna is available commercially or through reimbursed expanded access programs (EAP) or similar programs in multiple territories outside the U.S. Orders for Sephience and Translarna may be placed directly or through third-party distributors, who act as intermediaries without maintaining significant inventory. Outside the U.S., the ultimate payors are usually government authorities, institutions, or third-party health insurers. In 2025, four distributors each accounted for over 10% of net product sales. Products are shipped only after patient approval and prescription, with limited return rights. Some countries place centralized group purchase orders covering multiple months, resulting in fluctuations in quarterly sales.
Ptc Therapeutics Inc’s Comment on Sales, Marketing and Customers
In 2025, the company's product revenue was primarily derived from sales of Translarna for nmDMD, Emflaza for DMD, and Sephience for PKU. Sephience and Emflaza are commercially available throughout the United States and distributed through five specialty pharmacies that ship directly to patients based on physician prescriptions. Payors for these products in the U.S. are typically state health insurance programs or third-party health insurers. Sephience is also commercially available in the European Economic Area (EEA) and other regions. Translarna is available commercially or through reimbursed expanded access programs (EAP) or similar programs in multiple territories outside the U.S. Orders for Sephience and Translarna may be placed directly or through third-party distributors, who act as intermediaries without maintaining significant inventory. Outside the U.S., the ultimate payors are usually government authorities, institutions, or third-party health insurers. In 2025, four distributors each accounted for over 10% of net product sales. Products are shipped only after patient approval and prescription, with limited return rights. Some countries place centralized group purchase orders covering multiple months, resulting in fluctuations in quarterly sales.
Sources:
Ptc Therapeutics inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Ptc Therapeutics inc’s corporate clients.
For your research, we’ve provided 9 tables on Ptc Therapeutics inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
50.09 %